Novozymes Company Insiders
| NVZMY Stock | USD 55.75 0.01 0.02% |
Novozymes employs about 6.4 K people. The company is managed by 32 executives with a total tenure of roughly 218 years, averaging almost 6.0 years of service per executive, having 201.19 employees per reported executive. Break down of Novozymes' management performance can provide insight into the company performance.
| Peder Nielsen CEO CEO and Pres |
| Henrik Gurtler Chairman Chairman of the Board |
Novozymes |
Novozymes Management Team Effectiveness
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Novozymes Workforce Comparison
Novozymes AS is considered to be number one stock in number of employees category among related companies. The total workforce of Specialty Chemicals industry is now estimated at about 281,926. Novozymes holds roughly 6,438 in number of employees claiming about 2.28% of equities listed under Specialty Chemicals industry.
The company has Profit Margin (PM) of 0.21 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.26 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.26. Novozymes AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Novozymes AS Price Series Summation is a cross summation of Novozymes price series and its benchmark/peer.
Novozymes Notable Stakeholders
A Novozymes stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novozymes often face trade-offs trying to please all of them. Novozymes' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novozymes' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peder Nielsen | CEO and Pres | Profile | |
| Henrik Gurtler | Chairman of the Board | Profile | |
| Anders Lund | Executive Vice President Household Care & Technical Industries | Profile | |
| Prisca HavranekKosicek | CFO & Executive Vice President Corporate Functions | Profile | |
| Tina Fanoe | Executive Vice President Agriculture & Bioenergy | Profile | |
| Benny Loft | CFO and Executive VP | Profile | |
| Thomas Videbaek | COO and Executive VP of Bus. Devel. | Profile | |
| Thomas Nagy | Executive VP of Supply Operations | Profile | |
| Andrew Fordyce | Executive VP of Food and Beverages | Profile | |
| Kasim Kutay | Director | Profile | |
| Agnete RaaschouNielsen | Director | Profile | |
| Joergen Rasmussen | Independent Director | Profile | |
| Lena Halskov | Director, Employee Representative | Profile | |
| HeinzJuergen Bertram | Independent Director | Profile | |
| Anders Knudsen | Director, Employee Representative | Profile | |
| Lena Olving | Independent Director | Profile | |
| Mathias Uhlen | Independent Director | Profile | |
| Patricia Malarkey | Director | Profile | |
| Kim Stratton | Director | Profile | |
| Lars Green | Director | Profile | |
| Lars Koeppler | Independent Director, Employee Representative | Profile | |
| Tobias Bjorklund | Head of Investor Relations | Profile | |
| Ester Baiget | Pres CEO | Profile | |
| Pedro Fernandes | Head America | Profile | |
| Tue Micheelsen | VP Marketing | Profile | |
| Sebastian Sderberg | VP Acquisitions | Profile | |
| Martin Riise | Head of Investor Relations | Profile | |
| Graziela Malucelli | Supply Operations | Profile | |
| Per Falholt | Consultant | Profile | |
| Morten Rasmussen | Sustainability People | Profile | |
| Thomas Bomhoff | Head of Investor Relations | Profile | |
| MSc MSc | Ex CFO | Profile |
About Novozymes Management Performance
The success or failure of an entity such as Novozymes AS often depends on how effective the management is. Novozymes management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novozymes management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novozymes management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novozymes Unspn is traded on OTC Exchange in the United States.
The data published in Novozymes' official financial statements usually reflect Novozymes' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Novozymes AS. For example, before you start analyzing numbers published by Novozymes accountants, it's critical to develop an understanding of what Novozymes' liquidity, profitability, and earnings quality are in the context of the Basic Materials space in which it operates.
Please note, the presentation of Novozymes' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novozymes' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Novozymes' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novozymes AS. Please utilize our Beneish M Score to check the likelihood of Novozymes' management manipulating its earnings.
Novozymes Workforce Analysis
Traditionally, organizations such as Novozymes use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novozymes within its industry.Novozymes Manpower Efficiency
Return on Novozymes Manpower
| Revenue Per Employee | 2.7M | |
| Revenue Per Executive | 548.5M | |
| Net Income Per Employee | 572.5K | |
| Net Income Per Executive | 115.2M | |
| Working Capital Per Employee | 414.1K | |
| Working Capital Per Executive | 83.3M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |